Actualités et Activités de Abbisko Therapeautics
Dirigeants
Voir l'organigramme avec ses 6 principaux dirigeants
Biographies les plus recherchées chez Abbisko Therapeautics
- Jia Feng, Head of Human Resource
- Zidong Zhang, Chief Financial Officer
- Jing Ji, Chief Medical Officer
Créer une alerte
pour suivre les mouvements de dirigeants chez Abbisko Therapeautics.
Biotechnologie
Abbisko Therapeautics a 2 347 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et Genus (Royaume—Uni).
Actualités en fusion/acquisition en Biotechnologie.
- (publié le 28 mars 2025).
- Epic-Bio vient d'annoncer une levée de fonds de 68 millions de dollars. (publié le 28 mars 2025).
- Le nouveau nom de Ernexa Therapeutics est Ernexa Therapeutics. (publié le 26 mars 2025).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Abbisko Therapeautics
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutics announced a positive profit alert for the first half of 2024
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-2024 ESMO-GI | Abbisko Therapeutics presents new phase II clinical data of irpagratinib in combination with atezolizumab for advanced hepatocellular carcinoma
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko and Allist Pharmaceuticals Jointly Announce the Initiation of a Phase 2 Clinical Study Evaluating oral PD-L1 small molecule ABSK043 in Combination with Furmonertinib Mesylate Tablets for the Treatment of Advan
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutics Announces Irpagratinib, an Innovative FGFR4 inhibitor,has been Granted ODD by the U.S. FDA for the Treatment of HCC
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-2024 AACR | Abbisko Therapeutics Presented 3 Pre-clinical Research Results with Oral and Poster Presentations
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutics Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor – Pimicotinib（ABSK021）
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutics completed the First Patient Dose of Next-generation EGFR Exon20ins Inhibitor ABSK112
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-2024 ESMO TAT Oral Presentation — Abbisko Therapeutics presented preliminary first-in-human trial results of its selective FGFR2/3 inhibitor ABSK061
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-2024 AACR | Abbisko Therapeutics will present 3 pre-clinical research results with oral presentation and posters
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-US$70 million Arrived! Abbisko Therapeutics Announced it Received Upfront Payment Pursuant to the Licensing Agreement for Pimicotinib (ABSK021) with Merck
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Abbisko Therapeautics
- Abbisko Therapeautics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Abbisko Therapeautics sur LinkedIn, Twitter & YouTube en 1-click
